Market Insight

2024.07.18 10:34

Market News CHINARES PHARMA (03320) acquires Green Cross HK

(Infocast News) CHINARES PHARMA (03320) announced that CR Boya Bio-pharmaceutical has agreed to acquire an aggregate of 100% interest in Green Cross HK for a total cash Consideration of RMB1,820,000,000 (equivalent to HK$1,992,154,000) Green Cross HK is a holding company, which wholly owns all of its subsidiaries in the PRC, among which GC China is a blood products manufacturing company based in the PRC. GC China focuses on the research and development, production and sales of blood products. It currently has varieties of albumin, intravenous immunoglobulin, factor VIII, and fibrinogen. It has four plasma stations, and the plasma collection volume in 2023 would be 104 tons, with a compound growth rate of 13% from 2017 to 2023. (WL)

Data Source：INF